Table 3.

Structures and biochemical data for salicylamide derived WDR5 WBM-site inhibitors

Compound	R1	R2	R3	R4	FPA Kd (μM) a
7a			OH	H	0.746 ± 0.033
7b				Cl	0.298 ± 0.087
7c			OH	H	1.42 ± 1.59
7d				Cl	0.238 ± 0.089
7e			H	H	0.848 ± 0.187
7f			OH	H	0.204 ± 0.030
7g				Cl	0.190 ± 0.032
7h			H	H	1.08 ± 0.43
7i				Cl	0.128 ± 0.020
7j			OH	H	0.566 ± 0.024
7k				Cl	0.069 ± 0.034
7l			OH	H	0.779 ± 0.484
7m				Cl	0.362 ± 0.040
7n b			OH	H	0.046 ± 0.014
7o					0.757 ± 0.017
7p			H	H	1.88 ± 0.48
7q				Cl	0.220 ± 0.031
7r			OH	H	1.07 ± 0.30
7s				Cl	0.123 ± 0.05
7t			H	H	0.511 ± 0.050
7u				Cl	0.093 ± 0.001
7v			OH	H	0.167 ± 0.049
7w				Cl	0.045 ± 0.013
7x			H	Cl	0.215 ± 0.058
7y			OH	H	0.349 ± 0.174
7z	Cl			0.110 ± 0.057

^aData displayed is the average of at least 3 independent replicates ± standard deviation;

^bData is the average of two independent replicates.